NCT05209035 is a Phase 4 clinical trial of Trazodone in Mild Cognitive Impairment, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT05209035?

NCT05209035 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT05209035?

Interventions in NCT05209035: Trazodone, Placebo.

What condition does NCT05209035 study?

NCT05209035 studies Mild Cognitive Impairment, Obstructive Sleep Apnea.

Is NCT05209035 still recruiting?

NCT05209035 is currently active, enrolled. Last updated 6 January 2026.

Last reviewed 2026-01-06 · How we verify

NCT05209035

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Trazodone in OSA-MCI

Active, enrolled Phase 4 Last updated 6 January 2026

What this trial tests

Phase 4 trial testing Trazodone in Mild Cognitive Impairment in 134 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 May 2022

Primary endpoint
2 May 2025

28 February 2026

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	134
Start date	10 May 2022
Primary completion	2 May 2025
Estimated completion	28 February 2026
Sites	1 location across Hong Kong

Drugs / interventions tested

Trazodone (trazodone) — full drug profile →
Placebo

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 60 to 80, any sex, with Mild Cognitive Impairment or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disease. Before progressing to AD, individuals may experience mild cognitive impairment (MCI). While these individuals with MCI have an increased risk of progressing to AD, emerging studies reveal that obstructive sleep apnea (OSA) is a risk factor for both MCI an well as AD. Thus, it is worthwhile to identify clinical management or interventions that retard the conversion of subjects with comorbid MCI and OSA and AD. A randomized, double-blind, placebo-controlled study proposed herein aims to examine the effect of trazodone on reducing level sST2 and protein markers that are associated with neurodegeneration in the plasma of subjects with comorbid OSA and MCI. In this 1-year study, 124 study participants will undergo a series of neurocognitive assessments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Trazodone

Trials testing the same drug.

NCT05299398 — Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone · Phase 1 · withdrawn
NCT05085808 — RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) · Phase 4 · not yet recruiting
NCT06281756 — Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia · EARLY_PHASE1 · recruiting
NCT05293600 — Rescue Pharmacotherapy for OSA · Phase 1, PHASE2 · recruiting
NCT05282550 — Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone · Phase 2 · recruiting

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05209035 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 6 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05209035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing